-
公开(公告)号：US10047103B2
公开(公告)日：2018-08-14
申请号：US15593534
申请日：2017-05-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09688695B2
公开(公告)日：2017-06-27
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
3.发明授权Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权咪唑并噻二唑和咪唑并哒嗪衍生物作为治疗血小板聚集的蛋白酶活化受体4（PAR4）抑制剂公开(公告)号：US09518064B2
公开(公告)日：2016-12-13
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , A61K38/12 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
4.发明申请IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑唑二酮衍生物公开(公告)号：US20150133446A1
公开(公告)日：2015-05-14
申请号：US14396807
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon
IPC: C07D513/04 , A61K31/506 , A61K31/5377 , A61K31/4355 , A61K31/433 , A61K31/4439
CPC classification number: C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
Abstract translation: 本发明提供式（I）的咪唑并噻二唑化合物，其中A，B，D，Rx，R1，R2，R3，X1，X2和s如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式， 其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作药物。
-
5.发明申请IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗血小板聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑吡嗪衍生物公开(公告)号：US20150119390A1
公开(公告)日：2015-04-30
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Monteal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/433 , A61K31/5377 , A61K31/513 , A61K31/437 , A61K31/497 , A61K31/506 , A61K31/4439
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract translation: 本发明提供式（I）的咪唑并噻二唑化合物; 其中W，Y，R0，R2，R4，Ra，Rb，X1，X2，X3和X4如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐，前药酯或溶剂化物形式，其中所有变量 如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
Patent Agency Ranking
公开(公告)号：US20200123160A1
公开(公告)日：2020-04-23
申请号：US16538917
申请日：2019-08-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07B59/00 , A61K51/04 , A61K31/55 , A61K31/5386 , A61K31/435 , A61K31/553 , A61K31/541 , A61K31/5377 , A61K31/5025 , A61K31/497 , A61K31/496 , A61K31/454 , A61K31/4439 , A61K31/433 , C07D513/04 , C07D519/00 , A61K45/06
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US10428077B2
公开(公告)日：2019-10-01
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US09862730B2
公开(公告)日：2018-01-09
申请号：US14396807
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon
IPC: C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
-
公开(公告)号：US20140135270A1
公开(公告)日：2014-05-15
申请号：US14074062
申请日：2013-11-07
Applicant: Ensemble Therapeutics Corp. , BRISTOL-MYERS SQUIBB COMPANY
Inventor： Robert M. Borzilleri , Yong Zhang , Michael M. Miller , Benjamin A. Seigal
IPC: C07K7/54
CPC classification number: C07K7/06 , C07D471/08 , C07D471/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07K7/56
Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Abstract translation: 公开了利用本发明化合物调节凋亡抑制剂（IAP）的活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病和失调性细胞凋亡障碍的疾病的方法。
-
10.发明公开公开(公告)号：US20230242535A1
公开(公告)日：2023-08-03
申请号：US17902618
申请日：2022-09-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/454 , A61K31/5386 , A61K31/496 , A61K45/06 , C07B59/00 , A61K31/4439 , A61K31/5025 , A61K31/497 , A61K31/435 , A61K51/04 , A61K31/55 , C07D519/00 , A61K31/553 , A61K31/5377 , A61K31/433 , C07D513/04 , A61K31/541
CPC classification number: C07D487/04 , A61K31/55 , A61K31/433 , A61K31/435 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/541 , A61K31/553 , A61K31/4439 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K45/06 , A61K51/0453 , C07B59/002 , C07D513/04 , C07D519/00 , C07B2200/05
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.064 seconds)
